Greenwich LifeSciences, Inc. (GLSI) shares are down on Monday morning trade, after reaching an all-time peak last week.
The company shares have spiked as the biopharma company announced zero percent recurrence of breast cancer in its GP2 Phase IIb clinical trial through a poster presentation. On December 09, the shares have reached a high of 158.07.
Currently, shares are at $44.36, down 20.28 percent from the previous close of $56.00. For the 52-week period, the shares have traded in a range of $3.26 to $158.07 on average volume of 613,778.
For comments and feedback contact: editorial@rttnews.com
